AnnJi Advances AJ201 into Phase 3 Trial for Kennedy’s Disease
AnnJi moves AJ201 (rosolutamide) into the pivotal Phase 3 ROMA-KD trial for spinal and bulbar muscular atrophy, also called Kennedy disease.
AnnJi Advances AJ201 into Phase 3 Trial for Kennedy’s Disease
AnnJi moves AJ201 (rosolutamide) into the pivotal Phase 3 ROMA-KD trial for spinal and bulbar muscular atrophy, also called Kennedy disease.
AAVantgarde Reports Updated Gene Therapy Data for Usher Syndrome and Stargardt Disease
AAVantgarde reports early AAVB-081 results in Usher 1B (7 of 12 gained a line of vision) and preclinical AAVB-039 data for Stargardt disease.
Genmab Reports Positive Rina-S Data in Platinum-Resistant Ovarian Cancer
Genmab reports a 45.9% response rate and 12.1-month response duration for Rina-S in platinum-resistant ovarian cancer. Data, safety and what is next.
BD to Invest $3 Billion in U.S. Medical Device Manufacturing, With Over $1 Billion Cited for Nebraska
BD plans a $3 billion US manufacturing expansion inside a $19 billion pledge tied to tariff relief. What is confirmed, and what is not.
Samfara Makes Debut Buyout With Danish API Maker Chr. Olesen Synthesis
London-based Samfara has made its first investment, backing a Danish maker of controlled-substance APIs. How the buyout works and what to watch.
AstraZeneca, Daiichi Sankyo and Summit Build a Cost-Sharing Cancer Trial Pact Around Datroway and Ivonescimab
Three companies, three assets, shared costs: how the AstraZeneca, Daiichi Sankyo and Summit trial pact works and what it signals for oncology deals.
TIL Healthcare Pharma Plant Blast in Andhra Pradesh’s Sri City Leaves Workers Dead and Injured
A boiler explosion at the TIL Healthcare plant in Sri City, Andhra Pradesh killed five workers and injured over 10 on 3 October; cause is under probe.
Roche Launches Newborn Screening Test for SMA, SCID, SCD
Roche launches a CE-marked newborn screening test that detects SMA, SCID and sickle cell disease in one assay on LightCycler systems; not sold in the US.
Rakovina and Celvion Partner on AI-Driven Cancer Therapy
Rakovina Celvion partnership uses the EMphora AI platform and real-world clinical data to guide ATR inhibitor development; no financial terms disclosed.
